MedTrace Logo

Safety and Efficacy of HRS-9190 Compared to Rocuronium for Bolus Maintenance in Adults

NCT07404579 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 103

Last updated 2026-05-29

No results posted yet for this study

Summary

The study will enroll adult patients scheduled for elective surgery requiring general anesthesia. Participants will be randomly assigned to receive either HRS-9190 for Injection or Rocuronium. The primary objective is to measure the duration from the last dose of the study drug until the recovery of neuromuscular function to a specific level (TOFr ≥ 90%). Secondary objectives include evaluating the onset time and duration of action following each dose, the total time adequate muscle relaxation is maintained during surgery, and the detailed pattern of neuromuscular recovery. Safety assessments will include monitoring of adverse events, vital signs, laboratory parameters, and other safety indicators throughout the study period. The hypothesis of this study is that HRS-9190 for Injection could provide effective neuromuscular relaxation, with a satisfied safety profile in the target patient population.

Conditions

  • Neuromuscular Blockade

Interventions

DRUG

HRS-9190

HRS-9190; high dose(under Inhalational Anesthesia)

DRUG

HRS-9190

HRS-9190; low dose(under Inhalational Anesthesia)

DRUG

HRS-9190

HRS-9190; high dose(under Intravenous Anesthesia)

DRUG

HRS-9190

HRS-9190; low dose(under Intravenous Anesthesia)

DRUG

Rocuronium

Rocuronium(under Inhalational Anesthesia).

DRUG

Rocuronium

Rocuronium(under Intravenous Anesthesia)

Sponsors & Collaborators

  • Jiangsu HengRui Medicine Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-03-06
Primary Completion
2026-05-15
Completion
2026-05-26

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07404579 on ClinicalTrials.gov